CLINICAL_TRIALS
trial_result
· 2016-04-26
Clinical Trial Update: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer [Phase 2]
Summary
Phase 2 biomarker identification trial of Tarceva (erlotinib) in patients with advanced pancreatic cancer. The trial results were posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-04-26